What is Alnylam Pharmaceuticals's long-term debt?

Alnylam Pharmaceuticals (ALNY) reported long-term debt of $0.00 in Q4 2022.

How has Alnylam Pharmaceuticals's long-term debt changed year-over-year?

Alnylam Pharmaceuticals's long-term debt decreased by 100.0% year-over-year, from $675.70M to $0.00.

What is the long-term trend for Alnylam Pharmaceuticals's long-term debt?

Over 2 years (2020 to 2022), Alnylam Pharmaceuticals's long-term debt has grown at a -100.0% compound annual growth rate (CAGR), from $191.28M to $0.00.

What does long-term debt mean?

Money the company has borrowed that doesn't need to be paid back for at least a year.

Non-Current Liabilities

Long-Term Debt

Alnylam Pharmaceuticals Long-Term Debt decreased by 100.0% to $0.00 in Q4 2022 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $675.70M to $0.00. Over 2 years (FY 2020 to FY 2022), Long-Term Debt shows a downward trend with a -100.0% CAGR.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Liabilities

CategoryLeverage

SignalContext dependent

VolatilityStable

First reportedQ3 2016

Last reportedQ4 2025

How to read this metric

An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.

Detailed definition

Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...

Peer comparison

Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.

Metric ID: long_term_debt

Historical Data

6 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q4 '22
Value	$433.15M	$433.80M	$675.70M	$676.71M	$677.72M	$0.00
QoQ Change	—	+0.1%	+55.8%	+0.1%	+0.1%	-100.0%
YoY Change	—	—	—	—	+56.5%	-100.0%

Range$0.00 – $677.72M

CAGR-100.0%

Avg YoY Growth-21.8%

Median YoY Growth-21.8%

Long-Term Debt at Other Companies

Agilent TechnologiesA View metric

AmgenAMGN View metric

Regeneron PharmaceuticalsREGN View metric

Gilead SciencesGILD View metric

PfizerPFE View metric

Merck & Co.MRK View metric

Frequently Asked Questions

What is Alnylam Pharmaceuticals's long-term debt?: Alnylam Pharmaceuticals (ALNY) reported long-term debt of $0.00 in Q4 2022.
How has Alnylam Pharmaceuticals's long-term debt changed year-over-year?: Alnylam Pharmaceuticals's long-term debt decreased by 100.0% year-over-year, from $675.70M to $0.00.
What is the long-term trend for Alnylam Pharmaceuticals's long-term debt?: Over 2 years (2020 to 2022), Alnylam Pharmaceuticals's long-term debt has grown at a -100.0% compound annual growth rate (CAGR), from $191.28M to $0.00.
What does long-term debt mean?: Money the company has borrowed that doesn't need to be paid back for at least a year.